PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2014

MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma.

Mouse / Radiation

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 24850900 ↗2014Reported benefit

MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma.

MouseRadiationSkh-1 hairlessFemalen = Acute study 50 mice with 5 per treatment per time point; ch…Oral gavage20 mg/kg per day, given as 100 microlitres per day in vehic…Acute study: 5 daily doses before UVB, with exposure 24 h after the last gavage…

Model: UVB irradiation of dorsal skin from Philips FS40 lamps: a single 2,240 J/m2 dose (1 minimal erythemic dose) for the acute study, and 1 minimal erythemic dose three times weekly on non-consecutive days for 10 weeks for the chronic carcinogenesis study

Pretreatment increased keratinocyte apoptosis and early p53 while reducing Ki67, cyclobutane pyrimidine dimers, phosphohistone H2A.X and myeloperoxidase. Chronically it reduced p53 foci density (p=0.0014), epidermal Ki67 (p=0.0168) and tumour burden at 18 weeks (p=0.0131), and no treated tumour pro…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.